期刊
NATURE COMMUNICATIONS
卷 10, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-08869-9
关键词
-
资金
- National Institute for Allergy and Infectious Disease (NIAID) [R41 AI131742]
- National Health and Medical Research Council of Australia (NHMRC) project [APP1100164]
- Overseas (Biomedical) Fellowship [APP1037373]
- University of Melbourne Early Career Researcher Grant Scheme [603107]
- National Science Foundation Graduate Research Fellowship [DGE-1143954]
- Potts Memorial Foundation Postdoctoral Fellowship
- Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award
- VaxNewMo
Chemical synthesis of conjugate vaccines, consisting of a polysaccharide linked to a protein, can be technically challenging, and in vivo bacterial conjugations (bioconjugations) have emerged as manufacturing alternatives. Bioconjugation relies upon an oligosaccharyltransferase to attach polysaccharides to proteins, but currently employed enzymes are not suitable for the generation of conjugate vaccines when the polysaccharides contain glucose at the reducing end, which is the case for similar to 75% of Streptococcus pneumoniae capsules. Here, we use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysaccharides containing glucose at their reducing end. In addition, we show that different vaccine carrier proteins can be glycosylated using this system. Pneumococcal bioconjugates are immunogenic, protective and rapidly produced within E. coli using recombinant techniques. These proof-of-principle experiments establish a platform to overcome limitations of other conjugating enzymes enabling the development of bioconjugate vaccines for many important human and animal pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据